Gilead challenges GSK with strong HIV drug data
February 14, 2017 at 03:47 AM EST
LONDON, Feb 14 (Reuters) - Gilead Sciences has thrown down a challenge to GlaxoSmithKline with good clinical trial results for an experimental HIV drug that works in the same way as the British group's successful dolutegravir.
